Biote Corp. announced its second quarter 2025 financial results on August 6, 2025, reporting total revenue of $48.9 million, a slight decrease from $49.2 million in the prior-year period. Procedure revenue decreased by 8.4%, while dietary supplement revenue increased by 30.4%.
The company's gross profit margin improved to 71.6% from 68.8%, primarily due to the vertical integration of its 503B manufacturing facility and effective cost management. Operating income increased 72.7% to $10.8 million, driven by higher gross profit and reduced operating expenses.
Net income for the quarter was $3.9 million, with diluted earnings per share attributable to Biote Corp. stockholders at $0.10. Adjusted EBITDA increased 19.1% to $15.2 million, and the Adjusted EBITDA margin expanded to 31.1%, benefiting from a shift in the annual marketing event and improved profitability.
Biote revised its fiscal 2025 revenue guidance to be greater than $190 million, down from the previously disclosed range of $202-$208 million. Fiscal 2025 Adjusted EBITDA guidance was also revised to be greater than $50 million, compared to the prior range of $59-$64 million.
The revised guidance reflects the anticipated time required for the recently initiated organizational restructuring to positively impact performance. The restructuring, which began in early May, included new leadership, expanded corporate talent, and an upgraded sales compensation structure, with a one-time charge of $0.6 million to $0.8 million incurred in Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.